GlassScriptPhysician profile
Silke Rempe
NPI 1770773087
$833.03
in general payments reported to CMS, 2019-2025
14 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.31 · 2022: $259 · 2023: $188 · 2024: $61.47 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $225.18 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Insmed, INC. | $186.32 | 2022-2025 | Arikayce |
| Electromed, INC. | $83.30 | 2022-2025 | Smartvest |
| Harmony Biosciences LLC | $68.72 | 2022 | |
| Mylan Specialty L.P. | $49.26 | 2022-2023 | Yupelri |
| Paratek Pharmaceuticals, INC. | $38.39 | 2022-2023 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $36.00 | 2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $27.59 | 2022 | |
| Advanced Respiratory, INC | $26.86 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $25.24 | 2022 | |
| Glaxosmithkline, LLC. | $22.20 | 2023 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $15.91 | 2021 | |
| Baxter Healthcare | $14.52 | 2022 | |
| Apria Healthcare LLC | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silke Rempe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.